174 related articles for article (PubMed ID: 20877453)
1. MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease.
Jurgens CK; Jasinschi R; Ekin A; Witjes-Ané MN; Middelkoop H; van der Grond J; Roos RA
PLoS Curr; 2010 Sep; 2():. PubMed ID: 20877453
[TBL] [Abstract][Full Text] [Related]
2. Characterization of multifocal T2*-weighted MRI hypointensities in the basal ganglia of elderly, community-dwelling subjects.
Glatz A; Valdés Hernández MC; Kiker AJ; Bastin ME; Deary IJ; Wardlaw JM
Neuroimage; 2013 Nov; 82():470-80. PubMed ID: 23769704
[TBL] [Abstract][Full Text] [Related]
3. Automated segmentation of multifocal basal ganglia T2*-weighted MRI hypointensities.
Glatz A; Bastin ME; Kiker AJ; Deary IJ; Wardlaw JM; Valdés Hernández MC
Neuroimage; 2015 Jan; 105():332-46. PubMed ID: 25451469
[TBL] [Abstract][Full Text] [Related]
4. Basal ganglia-cortical structural connectivity in Huntington's disease.
Novak MJ; Seunarine KK; Gibbard CR; McColgan P; Draganski B; Friston K; Clark CA; Tabrizi SJ
Hum Brain Mapp; 2015 May; 36(5):1728-40. PubMed ID: 25640796
[TBL] [Abstract][Full Text] [Related]
5. Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study.
Domínguez JF; Ng AC; Poudel G; Stout JC; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
J Neurol Neurosurg Psychiatry; 2016 May; 87(5):545-9. PubMed ID: 25952334
[TBL] [Abstract][Full Text] [Related]
6. Pathological characterization of T2*-weighted MRI contrast in the striatum of Huntington's disease patients.
Bulk M; Hegeman-Kleinn I; Kenkhuis B; Suidgeest E; van Roon-Mom W; Lewerenz J; van Duinen S; Ronen I; van der Weerd L
Neuroimage Clin; 2020; 28():102498. PubMed ID: 33395988
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal changes in functional connectivity of cortico-basal ganglia networks in manifests and premanifest huntington's disease.
Gargouri F; Messé A; Perlbarg V; Valabregue R; McColgan P; Yahia-Cherif L; Fernandez-Vidal S; Ben Hamida A; Benali H; Tabrizi S; Durr A; Lehéricy S
Hum Brain Mapp; 2016 Nov; 37(11):4112-4128. PubMed ID: 27400836
[TBL] [Abstract][Full Text] [Related]
8. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
[TBL] [Abstract][Full Text] [Related]
9. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
[TBL] [Abstract][Full Text] [Related]
10. Regional subcortical shape analysis in premanifest Huntington's disease.
Tang X; Ross CA; Johnson H; Paulsen JS; Younes L; Albin RL; Ratnanather JT; Miller MI
Hum Brain Mapp; 2019 Apr; 40(5):1419-1433. PubMed ID: 30376191
[TBL] [Abstract][Full Text] [Related]
11. Timing of selective basal ganglia white matter loss in premanifest Huntington's disease.
Zeun P; McColgan P; Dhollander T; Gregory S; Johnson EB; Papoutsi M; Nair A; Scahill RI; Rees G; Tabrizi SJ;
Neuroimage Clin; 2022; 33():102927. PubMed ID: 34999565
[TBL] [Abstract][Full Text] [Related]
12. Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington's disease.
van de Zande NA; Bulk M; Najac C; van der Weerd L; de Bresser J; Lewerenz J; Ronen I; de Bot ST
Neuroimage Clin; 2023; 39():103450. PubMed ID: 37327706
[TBL] [Abstract][Full Text] [Related]
13. Magnetization transfer imaging in 'premanifest' Huntington's disease.
Jurgens CK; Bos R; Luyendijk J; Witjes-Ané MN; van der Grond J; Middelkoop HA; Roos RA
J Neurol; 2010 Mar; 257(3):426-32. PubMed ID: 19823894
[TBL] [Abstract][Full Text] [Related]
14. Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease.
Jurgens CK; van de Wiel L; van Es AC; Grimbergen YM; Witjes-Ané MN; van der Grond J; Middelkoop HA; Roos RA
J Neurol; 2008 Nov; 255(11):1785-91. PubMed ID: 19156490
[TBL] [Abstract][Full Text] [Related]
15. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
[TBL] [Abstract][Full Text] [Related]
16. Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.
Chen L; Hua J; Ross CA; Cai S; van Zijl PCM; Li X
J Neurosci Res; 2019 Apr; 97(4):467-479. PubMed ID: 30489648
[TBL] [Abstract][Full Text] [Related]
17. Elevated brain iron is independent from atrophy in Huntington's Disease.
Dumas EM; Versluis MJ; van den Bogaard SJ; van Osch MJ; Hart EP; van Roon-Mom WM; van Buchem MA; Webb AG; van der Grond J; Roos RA;
Neuroimage; 2012 Jul; 61(3):558-64. PubMed ID: 22480728
[TBL] [Abstract][Full Text] [Related]
18. Cognitive Control, Learning, and Clinical Motor Ratings Are Most Highly Associated with Basal Ganglia Brain Volumes in the Premanifest Huntington's Disease Phenotype.
Misiura MB; Lourens S; Calhoun VD; Long J; Bockholt J; Johnson H; Zhang Y; Paulsen JS; Turner JA; Liu J; Kara B; Fall E;
J Int Neuropsychol Soc; 2017 Feb; 23(2):159-170. PubMed ID: 28205498
[TBL] [Abstract][Full Text] [Related]
19. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease.
Bartzokis G; Tishler TA
Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):821-33. PubMed ID: 10875443
[TBL] [Abstract][Full Text] [Related]
20. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers.
Politis M; Lahiri N; Niccolini F; Su P; Wu K; Giannetti P; Scahill RI; Turkheimer FE; Tabrizi SJ; Piccini P
Neurobiol Dis; 2015 Nov; 83():115-21. PubMed ID: 26297319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
